

# CONTINUING EDUCATION

## EDUCATIONAL OBJECTIVES

After participating in this activity, clinicians should be better able to

- Determine three of the most common causative agents for chemotherapy-induced peripheral neuropathy
- Describe the most common symptoms of chemotherapy-induced peripheral neuropathy
- Discuss the management options for chemotherapy-induced peripheral neuropathy

### Disclosure of Conflicts of Interest

The Nurse Practitioner Healthcare Foundation (NPHF) assesses conflict of interest with its instructors, planners, reviewers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by NPHF for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. NPHF is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in health care.

The **faculty**: Colleen H. Erb, MSN, ACNP-BC, AOCNP, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

The **planners, reviewers, and staff**: Fiona J. Shannon, MHS, FNP; Phyllis Arn Zimmer, MN, FNP, FAAN; Joyce Pagan; Kristen Childress, DNP, ARNP; Connie Morrison-Hoogstede, MN, ANP, AOCNP, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

### Disclosure of Unlabeled Use

This educational activity does not contain discussion of any published and/or investigational uses of agents that are not indicated by the FDA.

### Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of, or imply endorsement by, the Nurse Practitioner Healthcare Foundation, American Nurses Credentialing Center, or Haymarket Media Inc.

As this article contains only a review, participants have an implied responsibility to use this newly acquired information while also consulting other appropriate sources of information in order to gain full understanding of the topic.

## CIPN: Treatment preservation and prevention are the goals

Colleen H. Erb, MSN, ACNP-BC, AOCNP

### STATEMENT OF NEED/PROGRAM OVERVIEW

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, serious side effect that can lead to dose reductions or early discontinuation of chemotherapy, reducing the efficacy of cancer treatments. It can cause debilitating symptoms and also significantly impacts the patient's quality of life. This activity is designed to give an overview of the causes of CIPN, its symptoms, and possible prevention and treatment strategies. To date, no medications are approved for treatment or prevention of CIPN; therefore, this overview presents the most common agents currently under investigation.

### CE INFORMATION

**Title:** CIPN: Treatment preservation and prevention are the goals

**Release date:** October 15, 2011

**Expiration date:** October 15, 2013

**Estimated time to complete this activity:** 1.25 hours

Free continuing nursing education credit of 1.25 in **pharmacology** is available. After reading the article, go to [myCME.com](http://myCME.com) to register, take the posttest, and receive a certificate. A score of 80% is required to pass.

Please note that the posttest is available only on [myCME.com](http://myCME.com). The article may also be viewed at [OncologyNurseAdvisor.com](http://OncologyNurseAdvisor.com) and on the Nurse Practitioner Healthcare Foundation Web site: [www.nphealthcarefoundation.org](http://www.nphealthcarefoundation.org). For more information, contact Fiona Shannon at [fiona@nphealthcarefoundation.org](mailto:fiona@nphealthcarefoundation.org).

This continuing nursing education activity is provided by the Nurse Practitioner Healthcare Foundation (NPHF).

NPHF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

**Target audience:** This activity has been designed to meet the educational needs of registered nurses and nurse practitioners involved in the management of patients with cancer.

**Media:** Journal article and Web site ([myCME.com](http://myCME.com)); [OncologyNurseAdvisor.com](http://OncologyNurseAdvisor.com); [nphealthcarefoundation.org](http://nphealthcarefoundation.org))

**Co-provided by the Nurse Practitioner Healthcare Foundation and Haymarket Media Inc.**



**haymarket**

# CONTINUING EDUCATION


## EDUCATIONAL OBJECTIVES

After participating in this activity, clinicians should be better able to

- Determine three of the most common causative agents for chemotherapy-induced peripheral neuropathy
- Describe the most common symptoms of chemotherapy-induced peripheral neuropathy
- Discuss the management options for chemotherapy-induced peripheral neuropathy

# CIPN: Treatment preservation and prevention are the goals

Chemotherapy-induced peripheral neuropathy can lead to reduced doses that hinder treatment effectiveness or early discontinuation of therapy.



Pain in the root ganglion (foreground) in relation to the peripheral pathways of the spinal cord section (left, center)

COLLEEN H. ERB, MSN, ACNP-BC, AOCNP

Peripheral neuropathy is a serious side effect experienced by many patients receiving chemotherapy, and may lead to dose reductions or early discontinuation of treatment. It also significantly impacts the patient's quality of life. The overall incidence of chemotherapy-induced peripheral neuropathy (CIPN) is believed to be 30% to 40% but can vary depending on the chemotherapy agents used.<sup>1</sup> Many prescription medications and supplements have been investigated for the prevention of CIPN and for symptom management of the condition, but none are currently approved for this indication. This article presents the most common agents under investigation.

## UNDERSTANDING CIPN AND ITS CAUSES

Peripheral neuropathy is caused by nerve damage resulting in both sensory and motor nerve impairment. Manifestations are relative to which neurons—autonomic, motor, or sensory—are disrupted (Table 1);<sup>2</sup> the resultant pain can be severe and lead to functional disability.

Patient age, dose intensity, cumulative dose of administered chemotherapy agent, use of more than one neurotoxic chemotherapeutic agent, and other preexisting comorbidities are other contributing factors to CIPN.<sup>3</sup> The specific manifestations of neuropathy vary depending on

the type of drug used. Severity of CIPN is measured according to grading scales that determine a need for intervention or discontinuation of neurotoxic agents (Table 2).<sup>4,5</sup> The most common offending agents are the vinca alkaloids, taxanes, and platinum-based drugs, but neuropathy is also caused by many other agents as well (Table 3).<sup>1,6</sup>

**Platinum-based agents** These drugs, especially cisplatin and oxaliplatin (Eloxatin, generics), frequently cause sensory neuropathy symptoms. Although carboplatin can cause symptoms as well, manifestation is less common. Cisplatin-related CIPN is dose dependent. Patients receiving cisplatin experience decreased vibratory sense, a loss of deep tendon reflexes, and paresthesias. A unique finding in patients receiving cisplatin is neurosensory high-frequency hearing loss and tinnitus.<sup>1</sup> Oxaliplatin, unlike other platinum-based agents, causes unique paresthesias and muscle cramping enhanced by exposure to cold, including shortness of breath and difficulty swallowing due to cold-related pharyngolaryngeal dysesthesia. These symptoms usually begin within a few hours after infusion.<sup>1,3</sup>

**Taxanes** Higher cumulative doses of taxanes are strongly associated with increased incidence of CIPN. In comparison, docetaxel (Docetaxel, Taxotere, generics) is less neurotoxic than paclitaxel (Abraxane, generics) at high doses.<sup>3</sup> The most common symptoms are paresthesias and dysesthesias manifesting within 24 to 72 hours after infusion. Manifestations usually begin as proximal weakness, myalgias/arthralgias specifically in the knees and shoulders, and, less often, nocturnal leg cramps. These symptoms often resolve 4 to 7 days after infusion. Over time, more than 70% of patients receiving taxanes develop persistent distal extremity numbness, tingling, and burning pain.<sup>1</sup>

**Vinca alkaloids** These agents cause pain and paresthesias in the feet and hands as well as the loss of deep tendon reflexes;

## Motor neurons are located in the spinal cord, which offers more protection to these neurons, making motor neuropathy less common.

however, findings of autonomic neuron disruption are unique to this class of drug.<sup>1</sup> Vincristine frequently causes constipation, ileus, and erectile dysfunction. Therefore, assessment of bowel function prior to starting vincristine is essential.<sup>3</sup> Both vincristine and vinblastine can affect the cranial nerves, leading to vocal cord paralysis, jaw pain, or optic neuropathy (rare).<sup>1</sup>

**TABLE 1. Manifestations based on affected neurons<sup>2</sup>**

Autonomic	
• Anhidrosis	• Ileus
• Blurred vision	• Orthostasis
• Changes in taste	• Overflow incontinence
• Constipation	• Sexual impotence
• Dizziness	• Tinnitus
• Hearing loss	• Urinary retention
Motor	
• Cramps	• Spasms
• Difficulty with fine motor activities (writing or dialing a phone)	• Tremors
• Gait disturbances	• Weakness
• Paralysis	
Sensory	
• Burning	• Hypersensitivity to touch
• Decreased or absent pain sensation	• Numbness
• Decreased or absent touch sensation	• Tingling
• Electric-shock sensations	

**Other risk factors** Preexisting sensory neuropathy should be documented to ensure that providers can distinguish CIPN from the patient's preexisting condition. Other causes of sensory neuropathy include diabetes, HIV, congenital neuropathy, alcohol abuse, and other medications the patient may be taking. Sensory neuropathy may also be a symptom of the diagnosed disease itself. Those with preexisting neuropathy should be monitored closely as their neuropathy can worsen quickly.<sup>1</sup>

### PATHOPHYSIOLOGY OF CIPN

The peripheral nervous system (PNS) is very sensitive to the effects of certain chemotherapy agents. Unlike the central nervous system (CNS), the PNS is not protected by a vascular barrier (eg, the blood-brain barrier). The nerves of the PNS exit the vertebral bodies and subsequently innervate specific areas called *dermatomes*. Each PNS neuron consists of a single axon surrounded by a myelin sheath, a cell body, and dendrites. The sensory neurons are bundled together in the dorsal root ganglia. Motor neurons are located in the spinal cord itself, which offers more protection to these neurons, making motor neuropathy less common.<sup>7</sup>

In almost all cases, CIPN is symmetrical and begins distally (ie, at the toes or fingertips), and if not corrected, progresses

**TABLE 2. Grading scales for CIPN<sup>4,5</sup>**

Functions	Grade 1	Grade 2	Grade 3	Grade 4
<b>NCI CTCAE</b>				
Motor	<ul style="list-style-type: none"> <li>Asymptomatic</li> <li>Detected on examination</li> </ul>	<ul style="list-style-type: none"> <li>ADLs not effected</li> <li>Weakness that interferes with function</li> </ul>	<ul style="list-style-type: none"> <li>Interference with ADLs</li> <li>Needs assistance to walk</li> <li>Weakness</li> </ul>	<ul style="list-style-type: none"> <li>Paralysis</li> </ul>
Sensory	<ul style="list-style-type: none"> <li>Asymptomatic</li> <li>Loss or decrease in DTR or mild sensory alteration</li> </ul>	<ul style="list-style-type: none"> <li>Sensory alterations that interfere with function with no effect on ADLs</li> </ul>	<ul style="list-style-type: none"> <li>Any alteration that interferes with ADLs</li> </ul>	<ul style="list-style-type: none"> <li>Debilitating</li> </ul>
<b>ECOG CTC</b>				
Motor	<ul style="list-style-type: none"> <li>Subjective weakness</li> </ul>	<ul style="list-style-type: none"> <li>Mild weakness on examination</li> <li>No impairment of function</li> </ul>	<ul style="list-style-type: none"> <li>Weakness with impairment of function</li> </ul>	<ul style="list-style-type: none"> <li>Paralysis</li> </ul>
Sensory	<ul style="list-style-type: none"> <li>Loss of DTR</li> <li>Mild paresthesias</li> </ul>	<ul style="list-style-type: none"> <li>Mild to moderate objective sensory loss</li> </ul>	<ul style="list-style-type: none"> <li>Interference with function</li> <li>Severe objective sensory loss</li> </ul>	
<p><b>Key:</b> ADLs, activities of daily living; CIPN, chemotherapy-induced peripheral neuropathy; DTR, deep tendon reflexes; ECOG CTC, Eastern Cooperative Oncology Group common toxicity criteria; NCI CTCAE, National Cancer Institute common terminology criteria for adverse events.</p>				

proximally in a stocking-glove distribution.<sup>1</sup> Most cases of CIPN resolve slowly over time when the offending chemotherapy agent is reduced or stopped; however, CIPN may be irreversible in cases of severe damage or neuronal death. Patients can also experience *coasting*, wherein symptoms worsen even after cessation of the causative agent.<sup>1</sup>

**PREVENTIVE MEASURES**

Prevention is the best option for patients receiving neurotoxic agents. The only widely accepted treatment for CIPN is

**A later review of CONcePT showed numerically higher response rates and lower incidence of high-grade CIPN in patients who received CaMg.**

dose modification based on the extent of interference in the patient’s daily life and the impact on quality of life.<sup>3</sup> Patients with preexisting neuropathy are at greatest risk of developing CIPN; therefore, a careful history should be obtained before starting therapy. Extremely close monitoring is essential if the patient has preexisting neuropathy.

Supplements and medications have been tested in clinical trials for their CIPN-preventive properties (Table 4);<sup>3,6</sup> however, results are mixed. Although some agents appear

promising, clinical trials have not produced adequate evidence for recommending one agent over another.<sup>8</sup> An investigation of vitamin E showed very promising results with a decrease in CIPN.<sup>9</sup> A second trial, however, showed no significant differences between vitamin E and placebo in regard to grade 2 or greater CIPN, time to onset, chemotherapy dose reductions due to CIPN, or patient-reported symptoms.<sup>10</sup> Despite these conflicting results, vitamin E is a promising CIPN preventive, and other clinical trials to determine its efficacy are ongoing.

Investigators hypothesized that intravenous administration of calcium gluconate and magnesium sulfate (CaMg) may lessen CIPN in patients with oxaliplatin-induced neuropathy. One study showed intravenous CaMg before and after oxaliplatin infusions produced significant reductions in CIPN with no effect on treatment efficacy.<sup>11</sup> The Combined Oxaliplatin Neurotoxicity Prevention Trial (CONcePT) initially revealed significantly lower disease response to therapy and closed early; however, a later review of this trial demonstrated numerically higher response rates and lower incidence of high-grade CIPN in patients who received CaMg.<sup>12</sup> At this time, data that support the use of CaMg infusions is insufficient.

Glutathione has been studied by European investigators. The hypothesis behind its proposed effectiveness is it may inhibit accumulation of platinum-based agents in the dorsal root ganglia. In a randomized, double-blind, placebo-controlled study from Italy, a lower incidence of grade 3 or

greater CIPN with little impact on tumor response was seen in patients who received IV glutathione before oxaliplatin therapy.<sup>13</sup> Although this study was promising, it had a very small sample size. Other trials, although not as rigorous, have also shown lower incidence of grade 3 to 4 CIPN.<sup>14</sup>

### TREATMENT STRATEGIES

The effectiveness of many treatment options is anecdotal because the data are limited by a lack of well-conducted, large, randomized trials. However, resolution of symptoms may be achieved with tricyclic antidepressants (TCAs), anticonvulsants, opioids, or a topical analgesic in some patients.

**Tricyclic antidepressants**, such as amitriptyline, desipramine (Norpramin, generics), and imipramine (Surmontil, Tofranil, generics) are known to modulate the sodium channels and inhibit reuptake of norepinephrine and serotonin, thereby decreasing pain. Adverse effects associated with TCAs include anticholinergic effects, cardiac effects, and sedation, and patients with significant cardiac disease should not use these agents.<sup>1</sup>

**Anticonvulsants**, particularly gabapentin (Gralise, Neurontin, generics), are used quite often and have been investigated without any true recommendation for use. In a randomized trial, gabapentin treatment failed to show any reduction of symptom severity.<sup>15</sup>

**Opioids** have been used to treat CIPN-related pain and can be titrated to achieve maximal reduction of pain. Once maximal relief is achieved, the preferred modality is a long-acting opioid analgesic with short-acting opioids used for breakthrough pain. Adding a TCA or an anticonvulsant may lower the total dose of opioid needed in some patients.<sup>1</sup>

**Topical analgesics** may be effective. A study presented at the 2009 American Society of Clinical Oncology (ASCO) general meeting demonstrated modest but not statistically significant improvement in motor symptoms with baclofen/amitriptyline/ketamine (BAK) gel.<sup>16</sup> The other well-studied topical agent is capsaicin (Qutenza), which has had results ranging from significant pain reduction to worsening pain and burning.<sup>1</sup>

Some nonpharmacologic interventions may produce a benefit, including transcutaneous nerve stimulation, relaxation techniques, and exercise. None of these have been

**A referral to physical therapy or rehabilitation may be appropriate to increase functional status or resolve a balance problem.**

**TABLE 3. Chemotherapeutic agents that can cause CIPN<sup>1,6</sup>**

<b>Epothilones</b>
Ixabepilone (Ixempra Kit)
<b>Less common agents</b>
Arsenic trioxide (Trisenox)
Cytarabine (Cytosar-U, Depocyt, generics)
Etoposide
Hexamethylmelamine (altretamine [Hexalen])
Ifosfamide (Ifex, generics)
Methotrexate (Trexall, generics)
Procarbazine (Matulane)
<b>Novel agents</b>
Bortezomib (Velcade)
Thalidomide (Thalomid)
<b>Platinum-based agents</b>
Carboplatin
Cisplatin
Oxaliplatin (Eloxatin, generics)
<b>Taxanes</b>
Docetaxel (Docefrez, Taxotere, generics)
Paclitaxel (Abraxane, generics)
<b>Vinca alkaloids</b>
Vinblastine
Vincristine
<b>Key:</b> CIPN, chemotherapy-induced peripheral neuropathy.

extensively studied, and no true recommendation is available. A referral to physical therapy or rehabilitation may be appropriate to increase functional status for patients with functional impairment or a balance problem.<sup>1</sup>

### CONCLUSION

The discovery of new therapy combinations and medications that lead to longer patient survival has made the care of patients with cancer more complex. Although some promising CIPN-preventive measures are being investigated, no standard treatment modalities have been established. A comprehensive patient history and thorough neurologic assessment with early dose reduction are the most effective interventions. The evidence for prevention and treatment using other substances, including vitamin E, CaMg, and glutathione,

**TABLE 4. Agents investigated for CIPN-preventive properties<sup>3,6</sup>**

Acetyl-L-carnitine
Alpha-lipoic acid
Amifostine (Ethyol, generic)
Amitriptyline
Baclofen/amitriptyline/ketamine (BAK) gel
Calcium gluconate and magnesium sulfate (CaMg)
Capsaicin (Qutenza)
Desipramine (Norpramin, generics)
Erythropoietin
Glutamate
Imipramine (Surmontil, Tofranil, generics)
Insulin-like growth factor
Lidocaine topical (Lidoderm, generics)
Nerve growth factor
Nimodipine
Oxcarbazepine (Trileptal, generics)
Venlafaxine (Effexor, Pristiq, generics)
Vitamin B complex
Vitamin E

is inconsistent. Trials for their use are ongoing ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)); until these trials are completed, there are no definitive recommendations for their use. ■

**Colleen Erb** is a hematology-oncology nurse practitioner at Fox Chase Cancer Center, Philadelphia, Pennsylvania.

**REFERENCES**

1. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. *Clin J Oncol Nurs.* 2007;11(3):361-376.
2. Armstrong TS, Grisdale KA. Peripheral neuropathy. In: Camp-Sorrell D, Hawkins RA, eds. *Clinical Manual for the Oncology Advanced Practice Nurse.* 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2006:909-918.
3. Cavaletti G, Alberti P, Frigeni B, et al. Chemotherapy-induced neuropathy. *Curr Treat Options Neurol.* 2011;13(2):180-190.
4. Eastern Cooperative Oncology Group (ECOG) Common toxicity criteria. ECOG Web site. [http://ecog.dfci.harvard.edu/general/common\\_tox.html](http://ecog.dfci.harvard.edu/general/common_tox.html). Accessed September 30, 2011.
5. Cancer Therapy Evaluation Program (CTEP). Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC).

National Cancer Institute Web site. [http://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm#ctc\\_40](http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). Accessed September 30, 2011.

6. Wolf S, Barton D, Kottschade L, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. *Eur J Cancer.* 2008;44(11):1507-1515.
7. Sugeran RA. Structure and function of the neurologic system. In: McCance KL, Huether SE, eds. *Pathophysiology: The Biologic Basis for Disease in Adults and Children.* St Louis, MO: Elsevier Mosby; 2006: 411-446.
8. Bhutani M, Colucci PM, Laird-Fick H, Conley BA. Management of paclitaxel-induced neurotoxicity. *Oncol Rev.* 2010;4(2):107-115.
9. Argyriou AA, Chroni E, Koutras A, et al. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of Vitamin E supplementation. *J Pain Symptom Manage.* 2006;32(3):237-244.
10. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial [published online ahead of print October 9, 2010]. *Support Care Cancer.*
11. Gamelin L, Boisdrion-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. *Clin Cancer Res.* 2004;10(12 pt 1):4055-4061.
12. Hochster HS, Grothey A, Shpilsky A, Childs BH. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. In: Proceedings from 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 280.
13. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effects of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. *J Clin Oncol.* 2002;20(16):3478-3483.
14. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Ann Oncol.* 1997;8(6):569-573.
15. Rao RD, Michalak JC, Sloan JA, et al; North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled crossover trial (N00C3). *Cancer.* 2007;110(9):2110-2118.
16. Barton DL, Wos E, Qin R, et al. A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA. 2009 ASCO Annual Meeting Proceedings. *J Clin Oncol.* 2009;27(15 suppl):9531.

**TO TAKE THE POSTTEST FOR THIS CE ACTIVITY and apply for 1.25 contact hours, please go to [myCME.com](http://myCME.com).**